A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies | Zendy

Eric J. Bow | Zendy; Coleman Rotstein | Zendy; Gary A. Noskin | Zendy; Morris Re | Zendy; Anthony P. Schwarer | Zendy; Brahm H. Segal | Zendy; John F. Seymour | Zendy; Jeff Szer | Zendy; Stephen Sanche | Zendy

Open Access

A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies

Author(s) -

Eric J. Bow,

Coleman Rotstein,

Gary A. Noskin,

Morris Re,

Anthony P. Schwarer,

Brahm H. Segal,

John F. Seymour,

Jeff Szer,

Stephen Sanche

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/505393

Subject(s) - cefepime , piperacillin/tazobactam , medicine , febrile neutropenia , piperacillin , tazobactam , odds ratio , clinical endpoint , randomized controlled trial , neutropenia , surgery , antibiotics , chemotherapy , antibiotic resistance , microbiology and biotechnology , genetics , imipenem , bacteria , pseudomonas aeruginosa , biology

The empirical treatment of febrile, neutropenic patients with cancer requires antibacterial regimens active against both gram-positive and gram-negative pathogens. This study was performed to demonstrate the noninferiority of monotherapy with piperacillin-tazobactam, compared with cefepime.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research